Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
546.12
-11.84 (-2.12%)
At close: Sep 4, 2026, 4:00 PM EDT
545.00
-1.12 (-0.21%)
After-hours: Sep 4, 2026, 7:57 PM EDT

Vertex Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
4,4053,953-535.63,6203,3222,342
Depreciation & Amortization
190.9178.6182169.5148.3125.6
Other Amortization
31.231.225.211.8--
Asset Writedown & Restructuring Costs
-379----
Loss (Gain) From Sale of Investments
----149.1-17.1
Stock-Based Compensation
689.1685.9698.5581.2491.3441.4
Other Operating Activities
-355-397.4-347.9-579.1-321.6-143.3
Change in Accounts Receivable
-259.7-347.3-99.3-84.1-358.6-274.7
Change in Inventory
-333.9-524.2-517.3-322.9-136.4-92.8
Change in Accounts Payable
-28.136.849.548.7120.831.9
Change in Other Net Operating Assets
-46.8-364.452.392.6715230.4
Operating Cash Flow
4,2933,631-492.63,5374,1302,644
Operating Cash Flow Growth
11.61%---14.35%56.23%-18.75%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-496.8-437.6-297.7-200.4-204.7-235
Cash Acquisitions
-----295.9-
Sale (Purchase) of Intangibles
---187.7-58--
Investment in Securities
-444.7-483.1-3,231-2,852227.3-105.9
Other Investing Activities
58.7-24.7-54-31-47.8-
Investing Cash Flow
-882.8-945.4-3,770-3,142-321.1-340.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----28.3
Total Debt Issued
-----28.3
Long-Term Debt Repaid
--5.4-33.6-44.9-85.5-47
Total Debt Repaid
-5.4-5.4-33.6-44.9-85.5-47
Net Debt Issued (Repaid)
-5.4-5.4-33.6-44.9-85.5-18.7
Issuance of Common Stock
136.6127.7114.6134.6186.3102
Repurchase of Common Stock
-2,332-2,387-1,582-653.7-172-1,561
Other Financing Activities
3.83.76.21.83.5-
Financing Cash Flow
-2,197-2,261-1,495-562.2-67.7-1,478

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-40.890.9-42.626.9-29.2-13.4
Net Cash Flow
1,172515.6-5,800-139.73,712811.2

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,7963,194-790.33,3373,9252,409
Free Cash Flow Growth
8.47%---14.99%62.97%-19.55%
Free Cash Flow Margin
30.16%26.61%-7.17%33.81%43.95%31.80%
Free Cash Flow Per Share
14.8112.38-3.0612.8115.159.27
Levered Free Cash Flow
2,6282,5732,8003,5103,3072,402
Unlevered Free Cash Flow
2,6362,5812,8193,5383,3422,441

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
12.512.430.543.152.356.3
Cash Income Tax Paid
1,3711,5671,0821,6771,058476.3
Change in Working Capital
-668.5-1,199-514.8-265.7340.8-105.2
SEC Filings: 10-K · 10-Q